Komipharm International Balance Sheet Health
Financial Health criteria checks 3/6
Komipharm International has a total shareholder equity of ₩60.0B and total debt of ₩44.6B, which brings its debt-to-equity ratio to 74.3%. Its total assets and total liabilities are ₩118.6B and ₩58.6B respectively.
Key information
74.3%
Debt to equity ratio
₩44.59b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩14.82b |
| Equity | ₩60.02b |
| Total liabilities | ₩58.58b |
| Total assets | ₩118.60b |
Recent financial health updates
Is Komipharm International (KOSDAQ:041960) A Risky Investment?
Mar 27
Komipharm International (KOSDAQ:041960) Is Carrying A Fair Bit Of Debt
Dec 18
Recent updates
Is Komipharm International (KOSDAQ:041960) A Risky Investment?
Mar 27A Look At Komipharm International's (KOSDAQ:041960) Share Price Returns
Feb 26Is Komipharm International Co., Ltd.'s (KOSDAQ:041960) Shareholder Ownership Skewed Towards Insiders?
Jan 22Komipharm International (KOSDAQ:041960) Is Carrying A Fair Bit Of Debt
Dec 18Financial Position Analysis
Short Term Liabilities: A041960's short term assets (₩50.0B) do not cover its short term liabilities (₩52.2B).
Long Term Liabilities: A041960's short term assets (₩50.0B) exceed its long term liabilities (₩6.4B).
Debt to Equity History and Analysis
Debt Level: A041960's net debt to equity ratio (49.6%) is considered high.
Reducing Debt: A041960's debt to equity ratio has increased from 36.8% to 74.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A041960 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A041960 has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 25% each year.